Your SlideShare is downloading. ×
Curriculum Vitae
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Curriculum Vitae

430
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
430
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Curriculum Vitae Personal Name: Thomas Philip Shakespeare MBBS, MPH, FRANZCR, FAMS, Grad Dip Med (Clin Epi) Professional Address: Integrated Cancer Care Services, Coffs Harbour Health Campus, Locked Bag 812, Coffs Harbour, NSW, 2450. Contact: Phone: (02) 6656 5125 (work) Fax: (02) 6656 7019 Email: Thomas.Shakespeare@ncahs.health.nsw.gov.au ThomasShakespeare@gmail.com CME currency: Royal Australian and New Zealand College of Radiologists (RANZCR), 1999 – present. Singapore Specialist Accreditation Board, 2000–present.
  • 2. University Education M.B,B.S. (Bachelor of Medicine, Bachelor of Surgery) University of Sydney, NSW, Australia. Graduated 1992. Times of London World University Ranking (2004): 36 Graduate Diploma of Medicine (Clinical Epidemiology) University of Sydney, NSW, Australia. Graduated 2000 with High Distinction average (Weighted Average Mark 89.7). M.P.H. (Master of Public Health) Streams in Medical Education, Management and Public Health. University of New South Wales, NSW, Australia. Graduated 2003 with High Distinction average (Weighted Average Mark 85.5). Times of London World University Ranking (2004): 40 Specialty Qualifications FRANZCR (Fellow of the Royal Australian and New Zealand College of Radiologists) CE Eddy Prize awarded by RANZCR for Part I exams, Jan 1996. Fellow of the RANZCR, April 1999 – Present. FAMS (Fellow of the Academy of Medicine, Singapore) Fellow April 2002 – Present. Postgraduate Management Courses Clinician Leadership Course, 2004. Clinical Practice Improvement Programme (CPIP) Course, 2004. Financial Statements for Health Managers Course, 2004. Professional Memberships NSW Cancer Institute Urology Oncology Group Faculty of Radiation Oncology Genitourinary Oncology Group (FROGG) Post-Fellowship Education Committee, RANZCR NSW Cancer Institute Clinical Services Advisory Committee NSW Directors of Radiation Oncology Committee Royal Australian and New Zealand College of Radiologists (RANZCR) European Society for Therapeutic Radiology and Oncology (ESTRO) American Society for Therapeutic Radiology and Oncology (ASTRO) American Society of Clinical Oncology (ASCO) Singapore Society of Oncology (SSO)
  • 3. Singapore Radiological Society (SRS) Academy of Medicine, Singapore (AMS) Prizes and Honours 1. Part I Prize, FRANZCR. Awarded the “C.E. Eddy Prize for the most outstanding candidate at the Part I FRANZCR Examination", January 1996. 2. NSW Premier’s Gold Award: Primary Contact Awarded November 9 2007 to the NCAHS Project Team for the North Coast Cancer Institute Project. 3. Novartis Prize for best Scientific Research (Poster category): Principal Investigator. Awarded October 2001 at RANZCR Annual Scientific Meeting, Melbourne, Australia. 4. Novartis Prize for best Scientific Research (Poster category): Principal Investigator. Awarded October 2002 at RANZCR Annual Scientific Meeting, Adelaide, Australia. 5. Chris Atkinson Prize for best research in Quality Assurance: Co-investigator. Awarded October 2002 at RANZCR Annual Scientific Meeting, Adelaide, Australia. 6. Human Manpower Development Project (HMDP) Consultant Fellowship Award Awarded January 2003 by the National Healthcare Group to attend IMRT training at University of California San Francisco. Value: $18,000. 7. Faculty Prize for best Scientific Research (Poster Category): Principal Investigator. Awarded October 2004 at RANZCR Annual Scientific Meeting, Perth, Australia. 8. Faculty Prize for Best Scientific Research (Poster Category): Co-Principal Investigator Awarded November 2006 at RANZCR Annual Scientific Meeting, Singapore 9. Wiley-Blackwell Best Exhibit Award for Radiation Oncology: Co-Investigator Awarded October 2007 at RANZCR Annual Scientific Meeting, Melbourne 10. CPIP Trophy and $2000 Prize Awarded 2005 at CPIP Graduation Ceremony by the National Healthcare Group for best Continuous Practice Improvement Project (CPIP) project: “Process Improvement for Spinal Cord Compression” project. Co-Principal Investigator. 11. Outstanding Project Award ($1000 prize). Awarded 2005 at Tan Tock Seng Hospital 3rd CPIP Convention for project: “Process Improvement for Spinal Cord Compression” project. Co-Principal Investigator. 12. Outstanding Poster Award ($500 prize) Awarded 2005 at National Healthcare Group, Singapore 5th Quality Week for project: “Process Improvement for Spinal Cord Compression” project. Co-Principal Investigator. 13. MOH Clinical Quality Poster Merit Award Awarded 2005 by Singapore Ministry of Health for project: “Process Improvement for Spinal Cord Compression” project. Co- Principal Investigator.
  • 4. 14. Honours in Statistics Assignment for FRANZCR Part II Awarded an "Honours +" in 1996/7 statistics assignment.
  • 5. Clinical and Teaching Appointments Director Area Cancer Services, March 2005 - present Director North Coast Cancer Institute (NCCI), Senior Consultant Radiation Oncologist, North Coast Area Health Service, NSW, Australia Associate Professor, March 2005 - present University of New South Wales, Australia Head of Oncology Services, January 2004 – March 2005 The Cancer Institute, Tan Tock Seng Hospital, Singapore Associate Professor, November 2004 – March 2005 National University of Singapore Consultant Radiation Oncologist, January 2000 – March 2005 Director of Training and Education, Radiotherapy Centre, National University Hospital (NUH), Singapore Clinical Senior Lecturer, August 2002 – Oct 2004 Faculty of Medicine, National University of Singapore (NUS) Lecturer, January 2001 – March 2005 Faculty of Health Sciences, Nanyang Polytechnic, Singapore Clinical Lecturer, August 2000 – July 2002. Faculty of Medicine, NUS, Singapore 50% Locum Consultant Radiation Oncologist/ May 1999 – January 2000 50% Radiation Oncology Research Fellow Joint Radiation Oncology Centre, N.S.W., Australia. Senior Radiation Oncology Registrar, 1998 - May 1999 Cancer Therapy Centre Liverpool Hospital, N.S.W., Australia. Radiation Oncology Registrar 1995 - 1997 Royal North Shore Hospital (RNSH), N.S.W., Australia. Senior Resident Medical Officer, RNSH. 1994 Intern and Resident, RNSH. 1992 - 1993
  • 6. Other Appointments Research Appointments 1. Appointed by ASTRO (American Society of Therapeutic Radiology and Oncology) to the Health Services Research Committee, 2004- present (5 year appointment). 2. Appointed to the ASTRO-NCI Cancer Expert Corps Taskforce, 2004. Journal Editorial and Review Appointments 1. Reviewer for The Lancet: 2001 – present. 2. Reviewer for Journal of Clinical Oncology: 2006 – present. 3. Reviewer for Cancer: 2003 – present. 4. Reviewer for Int. Journal of Radiation Oncology Biology Physics: 2001-present. 5. Reviewer for Respirology: 2002 – present. 6. Reviewer for International Journal of Epidemiology, 2003 - present. 7. Reviewer for Annals of the Academy of Medicine, Singapore: 2004 – present. Other International Appointments 1. Appointed by International Atomic Energy Agency (IAEA) has an international radiation oncology practice auditor 2. Appointed by the IAEA as the National Project Co-ordinator (NPC) for 3D-conformal radiotherapy planning 3. Panel of Advisors for BMJ Careers Advice Zone National Appointments 1. NHMRC Advanced Prostate Guidelines Full Working Group 2. NHMRC Advanced Prostate Guidelines Radiotherapy Working Committee 3. RANZCR Post Fellowship Education Committee State Appointments 1. NSW Radiotherapy Joint Advisory Committee 2. NSW Directors of Area Cancer Services Committee 3. Cancer Institute NSW Clinical Services Advisory Committee 4. Cancer Institute NSW CI-SCaT Committee 5. Cancer Institute NSW CI-SCaT Radiotherapy Reference Group (Chair) 6. Cancer Institute NSW NSWOG Urology Committee 7. Cancer Institute NSW Cancer Registries Committee Area and Hospital Appointments 1. NCAHS Clinical Services Advisory Committee (Chair) 2. CANNET Clinical Management Committee 3. NCAHS PP+D Committee (Lismore NCCI Unit) 4. NCAHS Area Cancer Management Committee 5. NCCI Site Management Committee
  • 7. 6. NCCI Radiotherapy Quality Committee
  • 8. Research and Education: Grants and Funding RNSH Medical and Ancillary Trust Fund Grant 1996 Value: $2500 Awarded July 1996 for the project: Intracranial epithelioid haemangio-endothelioma arising at site of resection of previously excised atypical meningioma RNSH Medical and Ancillary Trust Fund Grant 1997 Value: $3000 Awarded July 1997 for the project: Difficulties using the Franco-Italian Glossary in assessing toxicity of cervical cancer treatment. Cancer Institute NSW Value $138,212 Grant for an accredited Radiation Oncology Registrar, 2009 Value $130,000 Grant for NSW Cancer Institute Fellow, 2006 Value $74,460 Technology Enhancement Grant for Nasendoscope units 2006 Value $120,000 PI for Prostate Cancer MDT Grant Value $80,000 Supervisor for Lung Cancer MDT Grant Value $10,000 PI for Cancer Services accreditation pilot Grant Cancer Australia CANNET Project Value: $2,000,000 Lead for North Coast Area Health Service to develop a cancer network across 3 AHSs. NMRC Value: $800,000 Collaborator for a grant for a research project titled: The use of long wave ultrasound to upregulate endogenous bone morphogenetic proteins (BMP) and angiogenic factors (AF) in normal and irradiated bone. NHG Research Grants Principal Investigator for $40,000 grant for the National University Hospital Cancer Registry. Collaborator for $78,000 grant by NHG for a lung cancer research database Collaborator in $20,000 for unmet cancer needs research
  • 9. Collaborator in $48,297 for valproic acid and radiation in the lytic induction of EBV in NPC. Industry sponsorship Collaborator for Phase I study of gemcitabine in conjunction with vinorelbine and radiotherapy in the management of stage IIIB or medically non-resectable non-small cell lung cancer. Industry funded. Collaborator for multinational, multicentre, open label study to evaluate the efficacy of Cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). Industry funded. Education grants Principal Investigator for industry funding of $50,000 for the development and implementation of a Radiation Oncology training upgrade course for Vietnamese Radiation Oncologists. Service and Infrastructure Grants and Funding Federal Government Grants: Regional Cancer Centres of Excellence Primary Clinical Contact and coordinator of successful submission for $20 million grant Obtained for linear accelerators at Lismore and Port Macquarie, MRI at Coffs Harbour and PET scanner and patient accommodation at Lismore
  • 10. Research: Journal Publications Impact factors (published/in press) Impact factor for research publications: 100.754 Impact factor for first author research publications: 61.441 Impact factor for letters to the Editor: 43.469 Impact factor for published research abstracts: 75.206 Total Impact Factor: 219.429
  • 11. Published / In press 1. Shakespeare TP, Stevens MJ. Unilateral facial pain and lung cancer. Australas Radiol. 1996: 40: 45-46. 2. Shakespeare TP, Slancar MM, Mallik AR, Bell DR. CSF dissemination of a benign choroid plexus papilloma. Internal Medicine Journal (Aust NZ J Med). 1997: 27: 597-598. IF 1.518. 3. Shakespeare TP. Dissection of regional lymph nodes in cutaneous melanoma [letter]. Lancet. 1998: 351: 1885. IF 23.878. 4. Shakespeare TP, Ferrier AJ, Holecek MJ, Jagavkar R, Stevens MJ. Difficulties using the Franco-Italian Glossary in assessing toxicity of cervical cancer treatment. Int J Gynecol Cancer. 1998: 8: 51-55. IF 1.427. 5. Shakespeare TP, Holecek MJ. The importance of using confidence intervals when reporting results of studies in abstract form [Letter]. Int J Gynecol Cancer. 1998: 8: 165. IF 1.427. 6. Shakespeare TP, Holecek MJ. Defining involved field (IF) radiotherapy in Hodgkin’s disease [letter]. Australas Radiol. 1998: 42: 172-173. 7. Fryer JA, Biggs MT, Katz IA, Brazier DH, Shakespeare TP. Intracranial epithelioid haemangioendothelioma arising at site of resection of previously excised atypical meningioma. Pathology. 1998: 30: 95-99. IF 1.471. 8. Shakespeare TP, Holecek MJ. Should we be using confidence intervals when reporting results of oncology studies? [letter]. Int J Radiat Oncol Biol Phys. 1998: 41: 971-972. IF 4.556. 9. Jagavkar RS, Shakespeare TP, Stevens MJ. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma. Australas Radiol. 1998: 42: 157-158. 10. Shakespeare TP, Bourke RC. Systematic review of trials comparing antibiotic with placebo for acute cough in adults. Too few subjects were studied for useful conclusions to be drawn [letter]. BMJ. 1998: 317: 1014-5. IF 9.052. 11. Delaney G, Hui A, Berry M, Fowler A, Kneebone A, Barton M, Shakespeare T, Campbell G, Della-Fiorentina S, Brown K. Don't block the new kids [letter]. Australas Radiol. 43(4): 562, 1999 Nov. 12. Shakespeare TP, Gebski VJ, Veness MJ, Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet. 2001: 357: 1349–53. IF 23.878. 13. Shakespeare TP. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Comment. Curr News Med. 2001: 1:6. 14. Ong KJ, Back MF, Lu JJ, Shakespeare TS, Wynne CJ. Cultural attitudes to cancer management in traditional south-east Asian patients. Australas Radiol 2002; 46(4): 370-374. 15. Shakespeare TP, Dwyer MK, Mukherjee R, Yeghiaian-Alvandi R, Gebski VJ. Estimating risks of radiotherapy complications as part of informed consent: the high degree of variability between radiation oncologists may be related to experience. Int J Radiat Oncol Biol Phys. 2002; 54(3):
  • 12. 647-653. Editorial: Trotti A, Chin LJ. Adverse effects: a Pandora’s box for oncology pp 642- 646. IF 4.556. 16. Chua MST, Veness MJ, Morgan G, ShakespeareTP, Hehir A, Gebski V, Cakir B, Tiver KW. Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: Treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Australas Radiol 2002; 46(2): 174-179. 17. Shakespeare TP. Palliation of esophageal cancer: there is no clear winner [Letter]. Int J Radiat Oncol Biol Phys. 2003; 55(3): 849-850. IF 4.556. 18. Shakespeare TP, Lu JJ, Back MF, Liang S, Rahul RK, Wynne CJ. Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases. J Clin Oncol 2003; 21(11): 2156-2162. IF 11.810. 19. Mukherjee RK, Back MF, Lu JJ, Shakespeare TP, Wynne CJ. Hiding in the bunker: Challenges for a radiation oncology department operating in the Severe Acute Respiratory Syndrome outbreak. Australas Radiol. 2003 Jun;47(2):143-5. 20. Yoon KH, Wong A, Shakespeare TP, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12(2): 112-116. IF 2.400. 21. Back M, Shanmugan P, Shakespeare TP, Wynne CJ. Introducing the Intergroup 0016 protocol of adjuvant chemoradiotherapy in gastric cancer into clinical practice. Clin Oncol (RCR) 2003; 15:378-382. IF 1.288. 22. Shakespeare TP, Back MF, Lu JJ, Wynne CJ, Bloomfield L. Design of an internationally accredited radiation oncology training program incorporating novel educational models. Int J Radiat Oncol Biol Phys 2004; 59(4): 1157-1162. IF 4.556. 23. Balubarsaringam M, Lu JJ, Chong J, Tan TKL, Shakespeare TP. Tailoring distant metastatic imaging for patients with clinically localized undifferentiated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004; 58 (3): 688-693. IF 4.556. 24. Lu JJ, Shakespeare T, Goh BC, Chua ET, Back M, Mukherjee R, Wynne C, Kim Tan KSL. Adjuvant high-dose rate brachytherapy after chemoradiation for treatment of early T-stage nasopharyngeal carcinoma. Am J Clin Oncol 2004; 27(2): 132-13. IF 1.615. 25. Shakespeare TP, Mukherjee RK, Lu JJ, Wynne CJ, Kumar MB, Back MF. A comparison of RANZCR and Singapore-designed Radiation Oncology practice audit instruments: how does reproducibility affect future approaches to revalidation? Australas Radiol 2004; 48: 195-203. 26. Lu JJ, Shakespeare TP, Tan TKL, Goh BC, Cooper JS. Adjuvant Fractionated High-Dose-Rate Intracavitary Brachytherapy after External Beam Radiotherapy in T1 and T2 Nasopharyngeal Carcinoma. Head Neck 2004; 26: 389-395. IF 1.975. 27. Macbeth F, Stephens R, Abratt RP, Arriagada R, Ball D, Bezjak A, Billingham L, Crowley J, O’Brien M, Shakespeare T, Thompson E, van Meerbeeck J. An open letter to all members of the IASLC (Editorial). Lung Cancer 2004; 45(1): 119-120. IF 3.172. 28. Chung HT, Shakespeare TP, Wynne CJ, Mukherjee RK, Back MF. Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2004; 59(5): 1446-1453. IF 4.556.
  • 13. 29. Lim KH, Lu JJ, Wynne CJ, Back MF, Mukherjee R, Razvi K, Shakespeare TP. A Study of Complications arising from Different Methods of Analgesia used in Brachytherapy for Cervical Cancer. Am J Clin Oncol 2004; 27(5): 449-51. IF 1.615. 30. Tang JI, Shakespeare TP, Zhang XJ, Lu JJ, Liang S, Wynne CJ, Mukherjee RK, Back MF. Patient satisfaction with doctor-patient interaction in a radiotherapy center during the severe acute respiratory syndrome outbreak. Australas Radiol 2005; 49:304-311. 31. Tang JI, Back M, Shakespeare TP, Lu JJ, Mukherjee RK, Wynne C, Liang S. Interpreting the improved outcome of patients with central nervous system metastases managed in clinical trials compared with standard hospital practice. Australas Radiol. 2005 Oct;49(5):390-5. 32. Shakespeare TP, Thiagarajan A, Gebski VJ. Evaluation of the quality of radiotherapy randomized trials for painful bone metastases: Implications for future research design and reporting. Cancer 2005; 103(9): 1976-1981. IF 4.8. 33. Lu JJ, Shakespeare TP, Thiagarajan A, Zhang XJ, Tan LLS. Prospective Phase II Trial of Concomitant Boost Radiotherapy For Stage II Nasopharyngeal Carcinoma: An Evaluation of Response and Toxicity. Laryngoscope 2005;115(5):806-810. IF 1.617. 34. Shakespeare TP, Mukherjee RK, Back MF, Wynne CJ, Kumar MB, Zhang, Lu JJ. Audit with feedback (AWF) as a CME tool for radiation oncologists (ROs): evaluation of efficacy, perception, and cost-effectiveness. J Cancer Educ 2005; 20:216-221. IF 0.672. 35. Shakespeare TP, Back MF, Lu JJ, Mukherjee RK, Lee KM. External audit of clinical practice and medical decision-making in a new Asian oncology center: results and implications for developing and developed nations. Int J Radiation Oncology Biology Physics 2006; 64(3): 941- 947. IF 4.556. 36. Shakespeare TP, Lim K, Lee KM, Lu JJ, Mukherjee R, Back MF. Phase II study of the American Brachytherapy Society guidelines for the use of high dose rate (HDR) brachytherapy in the treatment of cervical carcinoma: is 45-50.4Gy radiochemotherapy plus 31.8Gy in 6 fractions HDR brachytherapy tolerable? Int J Gynecol Cancer 2006; 16: 277-282. IF 1.427. 37. Shakespeare TP, Gebski VJ, Thiagarajan A, Jay Lu J. Development of a spreadsheet for the calculation of new tools to improve the reporting of the results of medical research. Med Inform Internet Med 2006; 31(2): 121-127. IF 0.419. 38. Wong ASC, Soo RA, Lu LL, Loh KS, Tan KS, Hsieh WS, Shakespeare TP, Chua ET, Lim HL, and Goh BC. Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma. Ann Onc 2006; 17:1152-7. IF 4.319. 39. Leong CN, Shakespeare TP, Mukherjee R, Back MF, Lee KM, Lu JJ, Wynee CJ, Lim K, Tang J, Zhang X. Efficacy of an integrated continuing medical education (CME) and quality improvement (QI) program on radiation oncologist (RO) clinical practice. Int J Radiation Oncology Biology Physics 2006; 66: 1457-1460. IF 4.556. 40. Ma, X, Lu JJ, Loh KST, Shakespeare TP, Thiagarajan A, Goh BC, Tan KSL. Role of CT Imaging in Predicting Response of Nasopharyngeal Carcinoma to Definitive Radiation Therapy. Laryngoscope 2006; 116: 2162-2165. IF 1.617. 41. Tey J, Back MF, Shakespeare TP et al. The Role of Palliative Radiation Therapy in Symptomatic Locally Advanced Gastric Cancer. Int J Radiation Oncol Biology Physics 2007; 67(2): 385-8. IF 4.556.
  • 14. 42. Shakespeare TP, Tang JI, Shen L, Lu JJ, Mukherjee RK, Lee KM, Wynne CJ, Back MF. Does the implementation of oncology outpatient infection control measures adversely affect patient satisfaction with doctor-patient interaction? Sing Med J 2007; 48(3): 246-251. 43. Chapman A, Shakespeare T, Turner M. Improving access to radiotherapy for regional cancer patients – the National Radiotherapy Single Machine Unit Trial. Cancer Forum 2007; 31 (2): 74- 76. 44. Shakespeare TP. Toohey J. Radiation Oncology Clinical Audit: A Matter of Behaviour and Performance (Letter). Austral Radiol 2007 51(3): 298-9. 45. Shakespeare TP, Turner M, Chapman A. Is Rural Radiation Oncology Practice Quality as Good as the Big Smoke? Results of the Australian Radiotherapy Single Machine Unit Trial. Austral Radiol 2007; 51(4)381-5. 46. Lee K, Tsou I, Wong S, Yu C, Ming Z, Loh Y, Shakespeare T, Mukherjee R, Back M. Metastatic spinal cord compression as an oncological emergency: getting our ACT together. Int J Qual Health Care 2007; 19(6): 377-81. 47. Lu JJ, Kong L, Shakespeare TP, Loh KS, Zhang Q, Luke Tan KS, Lee KM. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma. Oral Oncol 2008; 44(7): 703-9 48. Shakespeare TP, Gebski V, Tang J, Lim K, Lu JJ, Zhang XJ, Jiang G. Impact of result presentation on research interpretation and medical decision-making: analysis of the PRIMER Collaboration randomized studies. Med Decis Making 2008 28(1):127-37. IF 1.822 49. Toohey J, Shakespeare TP, Morgan G. The RANZCR 2006 Peer review audit instrument. J Med Imaging Radiat Oncol. 2008; 52(4): 403-13. 50. Bell LJ, Shakespeare TP, Willis A. The importance of daily electronic portal imaging (EPI) in radiotherapy. J Med Imaging Radiat Oncol. 2008; 52(4): 414-18. 51. Tchoyoson Lim CC, Thiagarajan A, Sim CS, Khoo ML, Shakespeare TP, Ng I Craniospinal dissemination in teratocarcinosarcoma. J Neurosurg 2008; 109(2): 321-4. 52. Tang JI, Shakespeare TP, Lu JJ, Chan YH, Lee KM, Wong LC, Mukherjee RK, Back MF. Patients’ Preference for Radiotherapy Fractionation Schedule in the Palliation of Symptomatic Unresectable Lung Cancer. J Med Imag Radiat Oncol 2008; 52 (5): 497- 502. 53. Leong CN, Chung HT, Lee KM, Shakespeare TP, Mukherjee RK, Wong LC, Lu JJ, Tey J, Lim R, So JB, Back MF. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer J 2008; 14(4): 269-75. 54. Sidhom MA, Kneebone AB, Lehman M, Wiltshire KL, Millar JL, Mukherjee RK, Shakespeare TP, Tai KH. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 2008; 88(1): 10-9. 55. Aherne NJ, Steer AN, Warrier A, Shakespeare TP. Syndrome of inappropriate antidiuresis (SIAD) in a patient with rectal carcinoma undergoing preoperative radiation. Int J Colorectal Dis. 2009; 24: 861.
  • 15. Other publications. 1. Australian Cancer Network Management of Metastatic Prostate Cancer Working Party. Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer. Cancer Council Australia and Australian Cancer Networ, Sydney (2010). 2. Shakespeare TP. Evaluation of Audit with Feedback as a Continuing Medical Education tool for Radiation Oncologists [Dissertation: Master of Public Health Thesis]. Sydney: University of New South Wales, 2003. 3. Shakespeare TP. Confidence Calculator v1.0. Accessed July 2003. Statistical software downloadable from http://www.theshakespeares.com/confidence_calculator.html. 4. Shakespeare TP. New developments in confidence intervals that improve result reporting: Confidence levels, clinical significance curves and risk-benefit contours. University of Pittsburgh Supercourse Lecture. Accessed August 2003. http://www.pitt.edu/~super1/lecture/lec10421/001.htm 5. Shakespeare TJ, Shakespeare ZJ, Shakespeare TP. Range extensions for two species of Lycaenidae (Lepidoptera) to Coffs Harbour, New South Wales. Australian Entomologist 2009; 36 (1): 6. 6. Shakespeare TJ, Shakespeare ZJ, Shakespeare TP. Range extension and behavioural observations for Doleschallia bisaltide (Cramer) (Lepidoptera: Nymphalinae). Australian Entomologist 2010; 37 (1): 25-27. Research: Published Abstracts 1) Shakespeare TP, Skacel M, Seaton H, Traugott F. Simultaneous measurement of thermodilution and impedance cardiac output in anaesthetised cardiac patients. Royal Australasian College of Surgeons and Faculty of Anaesthetists GSM Abstract Book. 1991:35. 2) Shakespeare TP, Holecek MJ, Fryer JA, Biggs MT. Intracranial epithelioid haemangioendothelioma - is there a role for radiotherapy? Royal Australasian College of Radiologists 47th GSM Abstract Book. 1996: 280. 3) Shakespeare TP, Jagavkar R, Holecek MJ, Ferrier AJ, Stevens MJ. Difficulties using the Franco- Italian Glossary in grading toxicities of cervical cancer treatment. International Journal of Gynecologic Cancer. 1997: 9: 45. IF 1.427. 4) Shakespeare TP, Gebki VJ, Veness MJ, Simes RJ. Improving decision-making in oncology practice using confidence contours and clinical significance curves. Int J Radiat Oncol Biol Phys. 2000: 48 (Supplement): 155. IF 4.556. 5) Shakespeare TP, Jagavkar R, Holecek MJ, Ferrier AJ, Stevens MJ. Inadequacies of the Franco- Italian Glossary in grading toxicities of cervical cancer treatment. Royal Australasian College of Radiologists 48th GSM Abstract Book. 1997:274. 6) Gebski V, Shakespeare T, Veness M, Simes RJ. Improving the interpretation of clinical studies using clinical significance curves. Controlled Clinical Trials 2000: 21 (2S): 85S. IF 2.238. 7) Shakespeare TP, Dwyer MK, Mukherjee R, Yeghiaian-Alvandi R, Gebski VJ. Variability in estimating late normal tissue toxicity for patients receiving radiotherapy. Does experience influence what we are telling our patients? European J Cancer 2001: 37 (Supplement 6): 238. IF 3.706. 8) Shakespeare TP, Dwyer MK, Mukherjee R, Yeghiainan-Alvandi R, Gebski VJ. Australian radiation oncologists estimates of the risk of late complications: high variability may compromise informed consent. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2001: 383.
  • 16. 9) Shakespeare TP, Wynne CJ, Yoon KH, Wong A, Sivalingam P. High prevalence of antiphospholipid antibodies in cancer-related thrombosis. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2001: 382. 10) Shakespeare TP, Bloomfield L, Wynne CJ, Back MF. Development of a comprehensive evidence- based radiation oncology training program for a new radiotherapy centre. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2001: 372. 11) Shakespeare TP, Back MF, Chua ET, Wong A, Loh KS, Soo LK, Tok LT, Wang LZ, Lim HL, Tan L, Goh BC. Intensified concurrent chemoradiotherapy with 5-fluorouracil, paclitaxel, hydroxyurea and conventional radiotherapy (FTHX), is feasible in locally advanced nasopharyngeal carcinoma (NPC). Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2001: 367. 12) Wynne CJ, Shakespeare TP, Back MF, Lu JJ. Radiation oncology specialist training in Singapore. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2001: 356. 13) Shakespeare TP, Dwyer MK, Mukherjee R, Yeghiaian-Alvandi, Gebski VJ. Variability in estimating late normal tissue toxicity for patients receiving radiotherapy: does experience influence what we are telling our patients? Radiology 2001: 222 (Supplement): 335. IF 5.377. 14) Wong A, Loh KS, Lim E, Khoo CK, Chua ET, Shakespeare T, Lim HL, Tan L, Goh BC. Intensified concurrent chemoradiotherapy with 5-fluorouracil, paclitaxel, hydroxyurea and conventional radiotherapy (FTHX), is feasible in locally advanced nasopharyngeal carcinoma (NPC). Lung Cancer 2001: 34(1001): 35. IF 3.172. 15) Featherstone CJ, Beale PJ, Fife K, Shakespeare T, Bishop JF, Stockler M, Jackson M, Boyer MJ. Phase I study of gemcitabine, vinorelbine and radiotherapy in stage 3B or medically inoperable stage 1-3A non-small cell lung cancer. Proceedings of American Society of Clinical Oncology 2002; 21 (Vol 1): 335a. 16) Lu JJ, Shakespeare TP, Back M, Wynne C, Goh BC, Soo R, Tan KSL. A comparison of early tumour response for nasopharyngeal carcinoma after conventional radiotherapy or conventional radiotherapy followed by high dose-rate brachytherapy boost. Proceedings of the 6th NUS-NUH- Johns Hopkins Annual Scientific Meeting 2002:149. 17) Lu JJ, Shakespeare TP, Goh BC, Back M, Wynne C, Tan KSL. Adjuvant high-dose rate brachytherapy after concurrent chemoradiation for treatment of early T stage nasopharyngeal carcinoma. Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002: 149. 18) Shakespeare TP, Bloomfield L, Wynne CJ, Back MF, Lu JJ. Development of an accredited evidence-based radiation oncology training programme for a new Singaporean radiotherapy centre. Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002:151. 19) Shakespeare TP, Lu JJ, Back MF, Wynne CJ. The use of a decision board instrument to allow patient involvement in choosing radiotherapy fractionation schedule for painful bone metastases. Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002:151. 20) Shakespeare TP, Lu JJ, Loh T, Goh BC, Soo R, Tan L. Tailoring salvage therapy for residual nasopharyngeal carcinoma following radical radiotherapy: assessment of clinical, radiological and pathological factors at 4 and 12 months. Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002:152. 21) Shakespeare TP, Wynne CJ, Dwyer M, Mukherjee R, Gebski V. Large variability in estimating late normal toxicity for patients receiving radiotherapy. Does experience influence what we are telling our patients? Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002: 152. 22) Back M, Shanmugam P, Shakespeare T, Lui J, Wynee C. Introduction of new protocols into clinical practice: a quality assurance audit of the initial NUH experience with the US Intergroup 0116 protocol of adjuvant chemo-radiotherapy in gastric cancer. Proceedings of the 6th NUS-NUH- Johns Hopkins Annual Scientific Meeting 2002:116. 23) Tang J, Back M, Shakespeare T, Lui J, Wynne C. Selection of patients for aggressive management of cerebral metastases: interpretations from an audit of clinical prognostic factors at time of presentation. Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002:47. 24) Lim K, Shakespeare T, Back M, Lu J, Wynne C. A study of complications arising from different methods of analgesia used in brachytherapy for cervical cancer. Proceedings of the 6th NUS-NUH- Johns Hopkins Annual Scientific Meeting 2002:44.
  • 17. 25) Kumar MB, Shakespeare T, Lu J, Loh T, Tan L, Soo R, Goh BC, Chong J. Incidence of metastases at diagnosis in undifferentiated nasopharyngeal carcinoma. Proceedings of the 6th NUS-NUH-Johns Hopkins Annual Scientific Meeting 2002:41. 26) Shakespeare TP, Lu JJ, Back M, Wynne CJ. The use of a decision board instrument to allow patient involvement in choosing radiotherapy fractionation schedule for painful bone metastases. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2002: 295. 27) Shakespeare TP, Lu JJ, Loh T, Goh BC, Soo R, Tan L. Detection and natural history of residual disease at the primary site following radical radiotherapy for nasopharyngeal carcinoma. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2002: 296. 28) Shakespeare TP, Kumar M, Lu JJ, Loh T, Chong J, Soo R, Goh BC, Tan L. Utility and cost effectiveness of distant staging investigations for newly diagnosed nasopharyngeal carcinoma in Singaporeans. Royal Australian and New Zealand College of Radiologists 52nd Annual Scientific Meeting Abstract Book 2002: 296-7. 29) Shakespeare TP, Dwyer MK, Mukherjee R, Yeghiainan-Alvandi R, Gebski VJ, Wynne CJ. Australian radiation oncologists estimates of the risk of late complications: high variability may compromise informed consent. Australasian Radiology 2002; 46: A38. 30) Shakespeare TP, Wynne CJ, Yoon KH, Wong A, Sivalingam P. High prevalence of antiphospholipid antibodies in cancer-related thrombosis. Australasian Radiology 2002; 46: A38-39. 31) Shakespeare TP, Lu JJ, Loh T, Back MF, Wynne CJ, Hsieuh W-S, Goh BC, Soo R, Tan LKS. Tailoring salvage therapy for residual nasopharyngeal carcinoma (NPC) following radiotherapy (RT) or chemoradiotherapy (CRT): evaluation of clinical, radiological and pathological assessment at 4 and 12 months. Radiotherapy Oncology 2002; 64: S247. IF 3.304. 32) Lu JJ, Shakespeare TP, Tan LKS, Goh BC, Cooper JC. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in T1 and T2 nasopharyngeal carcinoma. American Radium Society 85th Annual Meeting Abstract Book. 33) Shakespeare TP, Mukherjee RK, Gebski V. Development of free statistical software enabling researchers to calculate confidence levels, clinical significance curves and risk-benefit contours. 12th International Congress of Radiation Research Abstract Book 2003: 261. 34) Shakespeare TP, Mukherjee RK, Lu JJ, Balubarsaringam MK, Wynne CJ. Radiation Oncology professional revalidation: is it the instrument and not the doctor that first needs to be valid? 12th International Congress of Radiation Research Abstract Book 2003: 250. 35) Shakespeare TP, Mukherjee RK, Lu JJ, Wynne CJ, Back MF. Audit with feedback (AWF) as a CME tool for radiation oncologists (ROs): evaluation of efficacy, perception, and cost-effectiveness. 12th International Congress of Radiation Research Abstract Book 2003: 66. 36) Tang JIH, Wynne CJ, Mukherjee RK, Back MF, Shakespeare TP, Lu JJ. Preventative measures to stop the spread of SARS at an outpatient based radiotherapy centre. 12th International Congress of Radiation Research Abstract Book 2003: 248. 37) Wynne CJ, Lu JJ, Mukherjee RK, Mahesh BK, Shakespeare TP, Back MF. Lessons from SARS for radiation oncologists. 12th International Congress of Radiation Research Abstract Book 2003: 250. 38) Shakespeare TP, Mukherjee RK, Lu JJ, Back MF, Wynne CJ. Evaluation of the Efficacy of a Targeted Continuing Medical Education (CME) Intervention for Radiation Oncologists (ROs). Int J Radiat Oncol Biol Phys 2003: 57; S224-5. IF 4.556. 39) Chung HT, Shakespeare TP, Wynne C, Lu JJ, Mukherjee R, Moravan V, Back M. Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2003; 57: S379-80. IF 4.556. 40) Shakespeare TP, Gebski VJ. Development of free statistical software enabling researchers to calculate confidence levels, clinical significance curves and risk-benefit contours. Ann Acad Med Sing, 2003: 32: S102. IF 0.419. 41) Shakespeare TP. Evaluating the published evidence for the efficacy of continuing medical education in radiation oncology. Ann Acad Med Sing, 2003: 32: S152. IF 0.419. 42) Shakespeare TP, Mukherjee RK, Lu JJ, Back MF, Wynne CJ. Evaluating the efficacy, participant satisfaction and cost-effectiveness of an oncology continuing medical education (CME) program. Ann Acad Med Sing, 2003: 32: S102. IF 0.419.
  • 18. 43) Shakespeare TP, Mukherjee RK, Lu JJ, Back MF, Wynne CJ Radiation oncology professional revalidation: is it the instrument and not the doctor that first needs to be valid? Ann Acad Med Sing, 2003: 32: S102. IF 0.419. 44) Tang J, Lu JJ, Wynee CJ, Mukherjee RK, Back MF, Shakespeare TP. Do severe acute respiratory syndrome (SARS) precautionary measures affect patient’s satisfaction with doctor-patient interaction? Ann Acad Med Sing, 2003: 32: S98. IF 0.419. 45) Zhang XJ, Lu JJ, Shakespeare TP, Cao J, Fu X, Jiang G. Primary non-Hodgkin’s lymphoma of the nasal cavity: evaluation of the prognostic significance of local tumour extension and combined modality treatment. Ann Acad Med Sing, 2003: 32: S100. IF 0.419. 46) Zhang XJ, Shakespeare TP, Lu JJ, Cao J, Fu X, Jiang G. Primary non-Hodgkin’s lymphoma of the nasal cavity: the evaluation of prognostic significance of local tumour extension and combined modality treatment. Int J Radiation Oncol Biol Phys, 2004, 60(1): S543. IF 4.556. 47) Leong C, Shakespeare TP, Mukherjee R, Back MF, Lee K, Lu JJ, Wynne CJ, Lim K, Tang J, Zhang X. Effect of an integrated continuing medical education (CME) and Quality Improvement (QI) program on radiation oncologist (RO) clinical practice. Int J Radiation Oncol Biol Phys, 2004, 60(1): S555-556. IF 4.556. 48) Shakespeare TP, Gebski V, Tang J, Lim K. Does result presentation influence physician interpretation of published research? Analysis of the Primer 1 randomized study. Ann Acad Med Sing, 2004, 33(5): S109. IF 0.419. 49) Shakespeare TP, Lu JDJ, Lee KM, Mukherjee RK, Back M. Evaluation of physician clinical performance in a new radiation oncology centre: quality equipment does not guarantee quality practice. Ann Acad Med Sing, 2004, 33(5): S109. IF 0.419. 50) Shakespeare TP, Zhang XJ, Gebski V, Tang J, Lim K, Lu JJ, Jiang G. Improving the interpretation of clinical research by oncologists: results of the PRIMER randomised study. Ann Acad Med Sing, 2004, 33(5): S109. IF 0.419. 51) Lim KHC, Shakespeare TP. Phase II study of the American Brachytherapy Society guidelines for the use of high dose rate brachytherapy in the treatment of cervical carcinoma. Implementation in an Asian society. Ann Acad Med Sing, 2004, 33(5): S124. IF 0.419. 52) Thiagarajan A, Lu JD, Shakespeare T, Zhang XJ, Tan LKS. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma. An evaluation of response and toxicity. Ann Acad Med Sing, 2004, 33(5): S124. IF 0.419. 53) Tang J, Shakespeare T, Lu J, Lee KM, Mukherjee R, Back M. Patient choice of radiotherapy fractionation schedule in the palliation of non-small cell lung cancer: design and validation of a decision board. Ann Acad Med Sing, 2004, 33(5): S153. IF 0.419. 54) Shakespeare TP, Leong CN, Back M, Lu JDJ, Lee KM, Mukherjee R. Impact of a Quality Improvement Program on radiation oncologist performance: evaluation of The Cancer Institute (TCI) model integrating continuing medical education, clinical quality assurance and international revalidation activities. Ann Acad Med Sing, 2004, 33(5): S153. IF 0.419. 55) Thiagarajan A, Shakespeare TP, Gebski V. Comparing radiation fractionation schedules for painful bone metastases: are we blinded to the quality of randomised evidence? Ann Acad Med Sing, 2004, 33(5): S170. IF 0.419. 56) Shakespeare TP, Mukherjee RK, Back M, Lu J, Lee K. External Audit of Clinical Practice and Medical Decision-Making in a New Asian Oncology Center: Results and Implications for Both Developing and Developed Nations. Int J Radiat Oncol Biol Phys 2005, 63 (2): S192-3. IF 4.556. 57) Lim K, Gebski V, Shakespeare T. Impact of Result Presentation on Research Interpretation and Medical Decision-Making: Analysis of the PRIMER Collaboration Randomized Studies. Int J Radiat Oncol Biol Phys 2005, 63 (2): S116-7. IF 4.556. 58) Holecek M, Bambach C, Shakespeare T, Juagavkar R. The effectiveness and low morbidity of axillary radiotherapy or surgery in the conservative treatment of early breast cancer. Int J Radiat Oncol Biol Phys 2005, 63 (2): S192-3. IF 4.556. 59) Tang JI, Back MF, Mukherjee R, Lee K, Lu J, Wong L, Shakespeare T. Patient Preference for Radiotherapy Fractionation Schedule in the Palliation of Symptomatic Unresectable Lung Cancer. Int J Radiat Oncol Biol Phys. 2006, 66 (3), S137. IF 4.556. 60) Lu JJ, Kong L, Loh K, Shakespeare TP, Thiagarajan A, Tan K.Prospective Phase II Trial of Concomitant Boost Radiotherapy for Stage II Nasopharyngeal Carcinoma Int J Radiat Oncol Biol Phys 2006, 66 (3), S448. IF 4.556. 61) Bell LJ, Shakespeare TP, Willis A. The Importance of Daily Electronic Portal Imaging (EPI) in Radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66 (3), S630. IF 4.556.
  • 19. 62) Toohey J, Shakespeare TP, Morgan G. The RANZCR 2006 revalidation audit instrument. Australas Radiol 2006, 50 (2), A63. 63) Bell LJ, Shakespeare TP, Willis A. The importance of daily electronic portal imaging (EPI) in radiotherapy. Australas Radiol 2006, 50 (2), A70. 64) Leong CN, Lee KM, Mukherjee RK, Lu JJ, Shakespeare TP, Wong LC, Woo T, Chung HT, Lim K, Tang J, Ming Z, Back MF. Outcome of concurrent chemotherapy and 3D-conformal radiation in management of rectal carcinoma: a Singapore experience. Australas Radiol 2006, 50 (2), A76. 65) Tang JI, Shakespeare TP, Lu JJ, Chan YH, Lee KM, Wong LC, Mukherjee RK, Back MF. Patient Preference for Radiotherapy Fractionation Schedule in the Palliation of Symptomatic Unresectable Lung Cancer. Australas Radiol 2006, 50 (2), A78. 66) Shakespeare TP et al. “Choosing my treatment”: Incorporating informational and decision-making needs into a preference compass. Australas Radiol 2007, 51, A88 67) Woo T, Chew L, Shakespeare T. START: A simple tool for the assessment of radiotolerance. Australas Radiol 2007, 51, A113 68) Aherne NJ, Wood M, Herden J, Greenham S, Shakespeare TP. A Prospective comparison of cone beam computed tomography (CBCT) versus electronic portal imaging (EPI) of implanted fiducial markers (FM) in online image guided radiotherapy (IGRT) of the prostate. J Med Imag Radiat Oncol 2008; 52 (suppl 2): A104. 69) Aherne NJ, Wood M, Herden J, Mincham S, Greenham S, Kovendy A, Hill J, Last A, Shakespeare TP. Fiducial merkers (FM) versus bone matching in patients receiving image guided radiation therapy (IGRT) following radical prostatectomy. J Med Imag Radiat Oncol 2008; 52 (suppl 2): A105. 70) Aheren NJ, Hoffman M, Greenham S, Daro K, Stephens R, Wirihana K, Shakespeare TP. Quality improvement in image guided radiation therapy delivery (IGRT) through automated data mining of a proprietary toxicity database. J Med Imag Radiat Oncol 2008; 52 (suppl 2): A113. 71) Faulkner K, Shakespeare TP, Kneebone A, Bichel-Findlay J, Sinclair S, Ward R. Utilization of the Cancer Institute NSW Standard Cancer Treatment Website (CI-SCaT). J Med Imag Radiat Oncol 2008; 52 (suppl 2): A114.
  • 20. National / International Conference Presentations 1) Simultaneous Measurement of Thermodilution and Impedance Cardiac Outputs in Anaesthetised Cardiac Patients. Presented at the Royal Australasian College of Surgeons and Faculty of Anaesthetists (RACS) 64th General Scientific Meeting, Darling Harbour, Sydney, May 6-9, 1991. 2) Intracranial epithelioid haemangioendothelioma - is there a role for radiotherapy? Presented at the Royal Australasian College of Radiologists' (RANZCR) 47th AGM, Perth Convention Centre, Perth, WA, October 5-9, 1996. 3) Difficulties using the Franco-Italian Glossary in grading toxicities of cervical cancer treatment. Presented at the International Gynecologic Oncology Biennial Meeting, Fukuoka, Japan, October 20-25, 1997. 4) Difficulties using the Franco-Italian Glossary in grading toxicities of cervical cancer treatment. Presented at the Royal Australasian College of Radiologists' (RANZCR) 48th AGM, 1997. 5) Improving decision-making in oncology practice using confidence contours and clinical significance curves. Presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 19th ASM, Boston, USA, 22-26 October, 2000. 6) Assessing clinical trials using confidence levels and risk benefit curves. Presented at the Society of Clinical Trialists (SCT) Conference, UK, 2000. 7) Variability in estimating late normal tissue toxicity for patients receiving radiotherapy. Does experience influence what we are telling our patients?. Presented at the Radiological Society of North America (RSNA) 87th Scientific Assembly and Annual Meeting, Chicago, Nov. 25-30, 2001. 8) Antiphospholipid Antibodies in Cancer-Related Thrombosis: Prevalence, Serotypes and Thrombotic Associations. Johns Hopkins Annual Oncology Symposium, Singapore 25 - 26 Aug, 2001. 9) Variability in estimating late normal tissue toxicity for patients receiving radiotherapy. Does experience influence what we are telling our patients?. Presented at the European Cancer Conference (ECCO / ESTRO), Lisbon, Portugal, 23 October, 2001. 10) High prevalence of antiphospholipid antibodies in cancer-related thrombosis. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 52nd ASM, Melbourne, Australia, 18-21 October, 2001. 11) Intensified concurrent chemoradiotherapy with 5-Fluorouracil, paclitaxel, hydroxyurea and conventional radiotherapy (FTHX) is feasible in locally advanced nasopharyngeal carcinoma (NPC). Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 52nd ASM, Melbourne, Australia, 18-21 October, 2001. 12) Radiation Oncology Specialist training in Singapore. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 52nd ASM, Melbourne, Australia, 18-21 October, 2001. 13) Development of an evidence-based Radiation Oncology training programme for a new Radiotherapy Department. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 52nd ASM, Melbourne, Australia, 18-21 October, 2001. 14) Pattern of response to definitive radiotherapy for nasopharyngeal carcinoma: comparison of clinical and pathological findings. Presented at American Radium Society (ARS) 84th Annual General Meeting, April 27 – May 1, Las Croabas, Puerto Rico, 2002. 15) Australian Radiation Oncologists’ estimates of the risk of late complications: high variability may compromise informed consent. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 52nd ASM, Melbourne, Australia, 18-21 October, 2001. Won the RANZCR ASM Prize for best poster. 16) Intensified concurrent chemoradiotherapy with 5-Fluorouracil, paclitaxel, hydroxyurea and conventional radiotherapy (FTHX) is feasible in locally advanced nasopharyngeal carcinoma (NPC). Presented at 2nd International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, October 4- 6, 2001. 17) Phase I study of gemcitabine (G), vinorelbine (V) and radiotherapy (RT) in stage IIIB or medically non- resectable stage I-IIIA non-small cell lung cancer (NSCLC). Presented at American Society of Clinical Oncology (ASCO) Orlando, Fl, May 18-21, 2002. 18) Tailoring salvage therapy for residual nasopharyngeal carcinoma (NPC) following radical radiotherapy (RT) or chemoradiotherapy (CRT): evaluation of clinical, radiological and pathological assessment at 4 and 12 months. Presented at European Society for Therapeutic Radiology and Oncology (ESTRO), Prague, 17-21 September, 2002.
  • 21. 19) Selection of patients for aggressive management of cerebral metastases: interpretations from an audit of clinical prognostic features at time of presentation. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 53rd ASM, Adelaide, 3-6 October, 2002. 20) The use of a decision board instrument to allow patient involvement in choosing radiotherapy fractionation schedule for painful bone metastases. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 53rd ASM, Adelaide, 3-6 October, 2002. 21) Detection and natural history of residual disease at the primary site following radical radiotherapy for nasopharyngeal carcinoma. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 53rd ASM, Adelaide, , 3-6 October, 2002. 22) Utility and cost-effectiveness of distant staging investigations for newly diagnosed nasopharyngeal carcinoma (NPC) in Singaporeans. Presented at the Royal Australian and New Zealand College of Radiologists (RANZCR) 53rd ASM, Adelaide, Australia, 3-6 October, 2002. 23) Development of free statistical software enabling researchers to calculate confidence levels, clinical significance curves and risk-benefit contours. Presented at the 12th International Congress of Radiation Research (ICRR), Brisbane, August 2003. 24) Radiation Oncology professional revalidation: is it the instrument and not the doctor that first needs to be valid? Presented at the 12th International Congress of Radiation Research (ICRR), Brisbane, August 2003. 25) Audit with feedback (AWF) as a CME tool for radiation oncologists (ROs): evaluation of efficacy, perception, and cost-effectiveness. Presented at the 12th International Congress of Radiation Research (ICRR), Brisbane, August 2003. 26) Preventative measures to stop the spread of SARS at an outpatient based radiotherapy centre. Presented at the 12th International Congress of Radiation Research (ICRR), Brisbane, August 2003. 27) Lessons from SARS for radiation oncologists. Presented at the 12th International Congress of Radiation Research (ICRR), Brisbane, August 2003. 28) Evaluation of the Efficacy of a Targeted Continuing Medical Education (CME) Intervention for Radiation Oncologists (ROs). Presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 45th ASM, Salt Lake City, UT , Oct. 19-23, 2003. 29) Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma. Presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) 45th ASM, Salt Lake City, UT , Oct. 19-23, 2003. 30) Development of free statistical software enabling researchers to calculate confidence levels, clinical significance curves and risk-benefit contours. Presented at the Singapore National Healthcare Group Annual Scientific Congress, Singapore 4-5 October, 2003. 31) Evaluating the published evidence for the efficacy of continuing medical education in radiation oncology. Presented at the Singapore National Healthcare Group Annual Scientific Congress, Singapore 4-5 October, 2003. 32) Evaluating the efficacy, participant satisfaction and cost-effectiveness of an oncology continuing medical education (CME) program. Presented at the Singapore National Healthcare Group Annual Scientific Congress, Singapore 4-5 October, 2003. 33) Radiation oncology professional revalidation: is it the instrument and not the doctor that first needs to be valid?. Presented at the Singapore National Healthcare Group Annual Scientific Congress, Singapore 4-5 October, 2003. 34) Results of the PRIMER 2 randomized study comparing P values plus 95% confidence intervals (P+CI), vs. P values plus confidence levels (P + CL) vs. P values plus 95% confidence intervals plus confidence levels (P+CI+CL) for optimizing oncologists’ interpretation of published clinical research. Presented at ESTRO, Amsterdam, 24-28 October 2004. 35) Evaluating the Published Evidence for the Efficacy of Continuing Medical Education in Radiation Oncology. Presented at RANZCR 55th ASM, Perth, 21-24 October 2004. 36) Does result presentation influence physician interpretation of published research? Analysis of the PRIMER 1 randomized study. Presented at RANZCR 55th ASM, Perth, 21-24 October 2004. 37) Improving the interpretation of clinical research by oncologists: results of the PRIMER 2 randomized study. Presented at RANZCR 55th ASM, Perth, 21-24 October 2004. 38) Impact of a Quality Improvement Program on Radiation Oncologist Performance: evaluation of the TCI- Singapore model integrating Continuing Medical Education, clinical Quality Assurance and international revalidation activities. Presented at RANZCR 55th ASM, Perth, 21-24 October 2004. 39) Evaluation of physician clinical performance in a new Asian radiation oncology centre: quality equipment does not guarantee quality practice. Presented at RANZCR 55th ASM, Perth, 21-24 October 2004. 40) Evolution of the RANZCR Audit Tool. Invited talk for RANZCR 56th ASM, Sydney, October 14-18, 2005.
  • 22. 41) Practical Applications of National Maintenance of Certification Audits. Invited talk for ASTRO 47th Annual Meeting, Denver Co., October 16-20, 2006. 42) External Audit of Clinical Practice and Medical Decision-Making in a New Asian Oncology Center: Results and Implications for Both Developing and Developed Nations. Presented at ASTRO 47th Annual Meeting, Denver Co., October 16-20, 2006. 43) Interpreting Research and Translating Results into Practice: Statistical vs Clinical Significance. Invited course for RANZCR 56th ASM, Sydney, October 14-18, 2005. 44) “Choosing my treatment”: Incorporating informational and decision-making needs into a preference compass. RANZCR 58th ASM, Melbourne, October 2007.
  • 23. Invited Lectures (National / International) 1. ASTRO Health Services / Outcomes Research in Oncology Symposium, San Diego, Sept 15-16, 2006. Invited speaker. 2. RANZCR 2005: Interpreting Research and Translating Results into Practice: Statistical vs Clinical Significance. Invited to run statistics course for RANZCR 56th ASM, Sydney, October 14-18, 2005. 3. RANZCR 2005: Evolution of the RANZCR Audit Tool. Invited talk for RANZCR 56th ASM, Sydney, October 14-18, 2005. 4. ASTRO 2005: Practical Applications of National Maintenance of Certification Audits. Invited talk and Chairman of Clinical Practice Quality Panel Session, ASTRO 47th Annual Meeting, Denver Co., October 16-20, 2006. 5. RANZCR 2004: Invited Chairman, Gastric Cancer Educational Session. October 21-24, Perth. 6. ASTRO 2003: Invited faculty speaker for Health Services Panel Program at the Annual Meeting, October 19-23, Salt Lake City. 7. EBM International Conference, Singapore, 2003: Invited speaker for EBM in Cancer Program. 8. Singapore National Healthcare Group Scientific Congress: Chairman of Congress, 18th August 2002. 9. Singapore Society of Oncology Annual Scientific Meeting 2003: Invited speaker. 10. Singapore Society of Oncology Annual Scientific Meeting 2004: Invited speaker. 11. Asia Pacific 13th Postgraduate Course in Palliative Medicine, Singapore, 2004: Invited panel member. 12. Changzhou City Tumor Hospital Opening Ceremony, Jiansu Province, China. March 12, 2004.